Esperion presents pediatric bempedoic acid data at European congress

May 26, 2026 8:00 AM

Esperion Therapeutics (NASDAQ: ESPR) presented data from a Phase 2 study of bempedoic acid in children and a secondary analysis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found